BridGene Biosciences Raises $28 Million to Advance Small Molecule Drug Development

BridGene Biosciences closes Series B+ financing round led by Bayland Capital for small molecule drug development.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here